Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Abbott Labs (ABT) PT Lowered to $125 at RBC Capital
April 18, 2024 6:19 AM EDTRBC Capital analyst Shagun Singh lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $128.00) while maintaining a Outperform rating.
The analyst comments "ABT delivered a Q1 Rev/EPS upside of $80MM/$0.03, respectively, and tightened its FY24 guidance range. Despite a strong Q1... More
Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
April 17, 2024 7:42 AM EDTAbbott Laboratories (NYSE: ABT) reported better-than-expected first-quarter top and bottom lines and narrowed its earnings guidance for the full fiscal 2024.
Shares fell over 2% in premarket trading Wednesday.
The healthcare company posted earnings per share (EPS) of $0.98, beating the consensus estimate of $0.96. Revenue... More
Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance
April 17, 2024 7:32 AM EDTAbbott (NYSE: ABT) reported Q1 EPS of $0.98, $0.02 better than the analyst estimate of $0.96. Revenue for the quarter came in at $9.96 billion versus the consensus estimate of $9.89 billion.
GUIDANCE:
Abbott sees FY2024 EPS of $4.55-$4.70, versus the consensus of $4.59.
Abbott... More